Sellas Life Sciences faces high risk in the Phase 3 REGAL AML trial for GPS. Click here to know why I rate the SLS stock a ...

– 86% (32/37) CRc and 73% (27/37) CR in newly diagnosed NPM1-m AML, with 68% (17/25) of CRc responders achieving molecular MRD negativity by central NGS – Median duration of complete response and ...

Syndax Pharmaceuticals is now a commercial-stage biopharma with two FDA-approved drugs: Revuforj and Niktimvo. Syndax's Revuforj leads in efficacy for AML, with rapid market penetration and a ...

NPM1-mutated AML prognosis was refined using a new genetic model integrating co-mutations, improving risk classification and ...

– Encouraging clinical activity with deep responses demonstrated in the KOMET-007 trial with the combination of 600 mg ziftomenib with 7+3 in newly diagnosed patients with NPM1-m and KMT2A-r AML – – ...

Kura Oncology and Kyowa Kirin announced that clinical data from the KOMET-007 trial, evaluating ziftomenib in combination with the standard chemotherapy regimen of cytarabine and daunorubicin (7+3) ...

New developments in the complex and rapidly changing world of acute myeloid leukemia (AML) promise to improve health outcomes for people with the disease. They include: Advances in diagnostics ...

Kura Oncology And Kyowa Kirin Report Combination Data For KOMZIFTITM (Ziftomenib) With Venetoclax And Azacitidine In Newly Diagnosed And Relapsed/Refractory AML. – 86% (32/37) CRc and 73% (27/37) CR ...